Sept. 13, 2024 – Obesity remains a significant health issue in the United States, even as weight loss drugs are getting more popular, according to new data from the CDC. On Thursday ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Obesity rates in the United States have finally started to show a decline, heading in the right direction for the first time in a decade likely due to the popularity of weight loss drugs like Ozempic.

Obesity and cancer form a troubling link in the United States. Over 40% of adults are obese, and more than 70% are overweight ...

New data released by the Centers for Disease Control and Prevention (CDC) has provided insight into the prevalence of obesity across the United States. The figures, initially from the 2023 Adult ...

Sen. Bill Cassidy reintroduced the Treat and Reduce Obesity Act (TROA) to address the obesity crisis through Medicare ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

In the past 20 years, the average rate of obesity among adults in the United States has risen by approximately 30 percent, but the rate of those with the most severe forms of obesity, or those with a ...

The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate.

Let that sink in. Genetics account for 70%, psychological factors 50%. GLP-1 and orforglipron work, but there are issues.

Obesity is a structural health crisis, disproportionately affecting Black and Brown communities in California. Proposed budget cuts threaten access to effective treatments.